|
 |
|
|||||||
|
|||||||||
Diabetes 54:1854-1862, 2005
© 2005 by the American Diabetes Association, Inc.
Pharmacogenetic Analysis of Rosiglitazone-Induced Hepatosteatosis in New Mouse Models of Type 2 Diabetes
1 The Jackson Laboratory, Bar Harbor, Maine
2 Group on Molecular and Cell Biology of Lipids, Canadian Institutes of Health Research, Edmonton, Alberta, Canada
3 Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
4 Linco Research, St. Charles, Missouri
Although thiazolidinediones suppress hyperglycemia in diabetic (NON x NZO)F1 males, these mice exhibit unusual sensitivity to drug-induced exacerbation of an underlying hepatosteatosis only rarely experienced in human patients. To establish the pharmacogenetic basis for this sensitivity, a panel of recombinant congenic strains (RCSs) with varying degrees of obesity and diabetes was generated by fixing selected NZO HlLt alleles on the diabetes- and hepatosteatosis-resistant NON/Lt background. Four new strains in this panel were exposed to chronic rosiglitazone treatment. Only one, NONcNZO8 (designated RCS8), exhibited an F1-like hepatosteatotic response. In both the F1 and RCS8 males, this adverse effect correlated with rosiglitazone suppression of already impaired hepatic phosphatidylcholine biosynthetic enzymes in both arms of the biosynthetic pathway, the phosphatidylethanolamine methyl- transferase pathway, and the CDP-choline pathway, including choline kinase and CTP-cholinephosphate cytidylyltransferase. This adverse response was not reproduced by CL316,243, a ß3-adrenergic receptor agonist with potent antihyperlipemic effects. Genome comparison showed that RCS8 differed from the other strains in carrying NZO-derived genome on virtually all of chromosome 16 and in smaller segments on chromosomes 6, 14, and 17. Thus, these RCSs present a panel of new mouse models exhibiting differential levels of obesity and diabetes as well as different drug responses. This panel can be used to screen for treatments for type 2 diabetes and its complications.
Address correspondence and reprint requests to Edward H. Leiter, PhD, The Jackson Laboratory, 600 Main St., Bar Harbor, ME 04609. E-mail: ehl{at}jax.org
Abbreviations:
PEMT, phosphatidylethanolamine methyltransferase; PPAR
, peroxisome proliferator–activated receptor-; QTL, quantitative trait locus; RCS, recombinant congenic strain; TZD, thiazolidinedione
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. S. Hartz, K. M. Nieman, R. L. Jacobs, D. E. Vance, and K. L. Schalinske Hepatic Phosphatidylethanolamine N-Methyltransferase Expression Is Increased in Diabetic Rats J. Nutr., December 1, 2006; 136(12): 3005 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Cui, J. Affourtit, K. R. Shockley, Y. Woo, and G. A. Churchill Inheritance Patterns of Transcript Levels in F1 Hybrid Mice Genetics, October 1, 2006; 174(2): 627 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Sher, C. Aoyama, K. A. Huebsch, S. Ji, J. Kerner, Y. Yang, W. N. Frankel, C. L. Hoppel, P. A. Wood, D. E. Vance, et al. A Rostrocaudal Muscular Dystrophy Caused by a Defect in Choline Kinase Beta, the First Enzyme in Phosphatidylcholine Biosynthesis J. Biol. Chem., February 24, 2006; 281(8): 4938 - 4948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Leiter, P. C. Reifsnyder, W. Zhang, H.-j. Pan, Q. Xiao, and J. Mistry Differential Endocrine Responses to Rosiglitazone Therapy in New Mouse Models of Type 2 Diabetes Endocrinology, February 1, 2006; 147(2): 919 - 926. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |